DEINOVE

Company Description

---

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial dark matter”. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance.

The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.

Year founded

---

2006

Served area

---

Worldwide

Headcount

---

50

Headquarters

---

Cap Sigma, ZAC Euromédecine II 1682 Rue de la Valsière, 34790 Grabels – France

Shares outstanding

---

29,110,552

IPO

---

April 21, 2010

Stock exchange(s)

---

Euronext Paris